The FDA has granted approval to late-stage biotech company Neurocentria Inc. to conduct a pivotal phase 2b/3 human clinical trial of its drug candidate NRCT-101SR compared with inactive placebo among adults with ADHD. Current ADHD treatments target monoamine synapses, whereas this drug candidate focuses on the novel target of glutamatergic synapses, according to a press release.